Advertisement
Advertisement
U.S. markets close in 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4050-0.0050 (-0.35%)
As of 03:02PM EST. Market open.
Advertisement

Cytosorbents Corporation

305 College Road East
Princeton, NJ 08540
United States
732 329 8885
https://www.cytosorbents.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees221

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip P. Chan M.D., Ph.D.CEO & Director667.47kN/A1970
Mr. Vincent J. Capponi M.S., MSPres & COO539.29kN/A1958
Ms. Kathleen P. Bloch CPA, CPA, M.B.A., MBACFO & Sec.462.11kN/A1955
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.Chief Medical Officer521.61kN/A1969
Ms. Terri Anne Powers M.B.A.VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Christian Steiner M.D.Exec. VP of Sales & MarketingN/AN/AN/A
Mr. Christopher Cramer MBA, MSVP of Bus. Devel.N/AN/AN/A
Dr. Robert H. Bartlett M.D.Co-Chairman of Cardiac Surgery Advisory Board & ConsultantN/AN/A1939
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Corporate Governance

Cytosorbents Corporation’s ISS Governance QualityScore as of November 28, 2022 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement